FOXO4-DRI

Also known as: D-retro-inverso FOXO4 peptide

Evidence Tier Chigh riskadvancednot approved

Preclinical senolytic peptide that disrupts FOXO4-p53 interaction to induce apoptosis in senescent cells.

Not Approved

This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.

No Human Data

No human exposure data has been identified for this substance. All available evidence comes from animal models or in vitro studies. Safety in humans is completely unknown.

Overview

FOXO4-DRI is a D-retro-inverso peptide designed to block the FOXO4-p53 interaction, inducing apoptosis in senescent cells. The concept has been validated preclinically but there is no standard human therapeutic framework. Mouse studies use 5 mg/kg IP on every-other-day schedules. Safety in humans is unknown; this is a high-risk category from a platform standpoint.

Research Details

Mechanism of Action

Blocks FOXO4-p53 interaction, inducing apoptosis in senescent cells (preclinical senolytic concept).

Study Dose Range

Mouse: 5 mg/kg IP every other day (limited administrations).

Administration Routes

subcutaneous

Onset / Timeline

Mouse outcomes assessed over days to weeks, depending on tissue model.

Expected Effects

Preclinical: selective elimination of senescent cells. No proven human benefit.

Adverse Effects

Unknown in humans; high-risk category.

Contraindications

No human data.

Interaction Notes

Unknown; do not propose combinations.

Related Goals

Longevity & Anti-Aging

Known Interactions

caution with IGF-1 LR3

FOXO4-DRI is a senolytic research peptide with limited human data; avoid combining with high-mitogenic axis in consumer protocols.

caution with PEG-MGF

High uncertainty + growth-factor cluster.

Available From

No vendors currently listed for this peptide.

Frequently Compared

MOTS-c

Mitochondrial-derived peptide studied in mouse models for metabolic homeostasis and insulin sensitivity.

Tier C

Epitalon

Pineal tetrapeptide discussed in aging literature for melatonin/circadian and telomerase pathways. Evidence gaps significant.

Tier C-D

Thymosin Alpha-1

Immunomodulatory peptide approved in various countries with broader clinical literature than most RUO peptides.

Tier B

GHK-Cu

Copper peptide complex with substantial topical/cosmetic literature for skin and hair repair.

Tier B-C

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.